Electromagnetic field (EMF) exposures affect many biological systems. The reproducibility of these effects is related to the intensity, duration, frequency, and pattern of the EMF. We have shown that exposure to a specific time-varying EMF can inhibit the growth of malignant cells. Thomas-EMF is a low-intensity, frequency-modulated (25-6 Hz) EMF pattern. Daily, 1 h, exposures to Thomas-EMF inhibited the growth of malignant cell lines including B16-BL6, MDA-MB-231, MCF-7, and HeLa cells but did not affect the growth of non-malignant cells. Thomas-EMF also inhibited B16-BL6 cell proliferation in vivo. B16-BL6 cells implanted in syngeneic C57b mice and exposed daily to Thomas-EMF produced smaller tumours than in sham-treated controls. In vitro studies showed that exposure of malignant cells to Thomas-EMF for > 15 min promoted Ca 2+ influx which could be blocked by inhibitors of voltage-gated T-type Ca 2+ channels. Blocking Ca 2+ uptake also blocked Thomas-EMF-dependent inhibition of cell proliferation. Exposure to Thomas-EMF delayed cell cycle progression and altered cyclin expression consistent with the decrease in cell proliferation. Non-malignant cells did not show any EMF-dependent changes in Ca 2+ influx or cell growth. These data confirm that exposure to a specific EMF pattern can affect cellular processes and that exposure to Thomas-EMF may provide a potential anti-cancer therapy.
Introduction
Several studies have shown associations between electromagnetic field (EMF) exposure and health effects, such as cancer incidence; however, the conclusions of these studies are sometimes difficult to reproduce and are therefore controversial. It is difficult to make direct associations between EMF exposure and health effects, since not all EMFs are equivalent [1] . For example, the biological effects of exposure to the 50-60 Hz EMF pattern from electrical power lines cannot simply be compared to the effects of exposure to the megaHz patterns generated by cell phones.
While most studies have focussed on the negative effects of EMF, specific EMFs have been shown to accelerate wound healing, enhance musculoskeletal recovery, and disrupt tumor growth [2] [3] [4] . The mechanisms by which EMF affects biological processes are not well established. Some investigators have proposed that non-specific processes such as the generation of heat, formation of free-radicals, and promotion of DNA damage are involved [5] [6] [7] . However, the energies typically associated with low frequency EMF are not sufficient to cause changes in chemical bonds and other models including ion resonance have been proposed [8, 9] .
We hypothesize that the ability of EMFs to interact with biological processes is dependent on the temporal patterns of the fields, similar to the way pharmaceuticals are dependent on their structures [10] . Therefore, the information contained in a specific time-varying pattern, conveyed at low intensities (5-10 μT), could influence biological processes. The characteristics of an EMF that elicit biological responses should be specific for wave pattern, field strength, and exposure configuration.
Much attention has focused on the ability of low-frequency (<300 Hz) magnetic fields with simple or symmetrical (sine-or square-wave) patterns to affect cellular processes [11] [12] [13] . Some studies have shown that exposure to a low frequency EMF pattern can promote cell proliferation [5, 14] while others have shown that EMF exposure inhibits cell proliferation [15] [16] [17] . Exposure of cells to 20-60 Hz EMF patterns has been shown to affect signal transduction pathways with effects on cAMP levels, MAP kinase activation, Ca 2+ -calmodulin kinase activation, or Ca 2+ channels being the most commonly reported [11, [18] [19] [20] .
Studies using asymmetrical EMF patterns, designed to mimic biologically-relevant processes, have shown that these complex EMF can influence specific biological processes [4, [21] [22] [23] . For example, the "Thomas" EMF pattern, a frequency modulated pattern designed to affect membrane activity associated with epileptic seizures, has been shown to have several biological effects. In particular, exposure of rodents to the Thomas-EMF pattern for 3 h/day has been associated with an increased analgesic response and to impaired memory performance on simple behavioral tasks [21, 24] . In these studies we showed that exposure to Thomas-EMF can also inhibit the growth of malignant cells by promoting Ca 2+ uptake through T-type Ca 2+ channels.
Materials and Methods

EMF exposure systems
The cultured cells or mice were exposed to Thomas-EMF, a weak 2-10 μT, frequency-modulated pattern, in a 4D box exposure system [21, 22] (Fig 1) . The 4D box for the in vitro studies was 12 cm on each side, fitted with 6 wire-wound solenoids, and placed in a water-jacketed CO 2 incubator at 37°C. The 4D box for in vivo exposures was made of plexiglass, 30 cm on each side, and fitted with six 50 ohm solenoids (28P-I-24VDC, Guardian Electric Manufacturing, Woodstock, IL, USA). The Thomas-EMF pattern was generated from a direct electrical current applied to the solenoids using a digital-to-analogue device controlled by the Complex© software on an IBM XT computer [21, 22] . Thomas-EMF is a digital file composed of 849 points each programmed for 3 msec (each cycle lasts 2.55 s) (Fig 2) . It is composed of 18 doublet peaks (each singlet is 6 ms) with gradually increasing intervals; a 3 ms interval for the first 5 repeats (25Hz) to a 120 ms interval (6 Hz) for the last 5 repeats. The reverse Thomas-EMF shows the same pattern except that it proceeds from 6 Hz to 25 Hz.
Cell lines
B16-BL6 (mouse melanoma) [25] and HSG (salivary gland) [26] were maintained in Dulbecco's Modified Essential Medium (DMEM, Hyclone, Logan, UT) containing 10% fetal bovine serum (Hyclone), 100 μg/ml streptomycin, and 100 U/ml penicillin (Invitrogen, Burlington, ON) at 37°C in 5% CO 2 .
Cell proliferation
The cells were plated on day 0 at 20-30% confluence and exposed to Thomas-EMF or sham conditions for 1 h/day. Cell number was measured each day using a hemocytometer to count 8 fields for trypan blue-excluding cells and the mean ± SD determined for each of at least 3 experiments conducted on different days. For some experiments, the cells were treated with calcium channel activators or inhibitors for 30 min prior to exposure and media changed after exposure. Percent inhibition of cell proliferation was calculated as the difference in cell number between sham and Thomas-EMF treated cultures divided by the sham control [(shamThomas)/sham Ã 100%].
In vivo EMF exposure experiments in mice
A total of 35 male C57b mice (in 2 blocks of 25 and 10 animals conducted about 6 months apart) were used (Charles River, Pointe-Claire, QB). All procedures were approved by the Laurentian University Animal Care Committee in accordance with Canadian Council for Animal Care guidelines. The mice were housed in disposable plastic cages with 5 mice/cage, at 20-21°C, a 12:12 light:dark cycle, and fed a standard mouse diet and water ad libitum. For experiments, each mouse was injected subcutaneously in the right hind flank with 10 6 B16-BL6 cells and randomly assigned to the sham or Thomas-EMF conditions. Mice were transferred to the 4D in vivo exposure system for 3 h each day, in the absence of food and water during treatment, starting the day after injection of the tumour cells and continuing until the day of sacrifice. Tumour growth was allowed to progress for 18-21 days for experiment 1 and 15-16 days for experiment 2 and then the tumours were excised and the diameter and weight measured. Tumour samples from the mice in experiment 2 were fixed in EFA (70% ethanol, 1.8% formaldehyde, and 0.75 N acetic acid), embedded in paraffin, and sectioned for immunohistochemical analysis [22] . The slides were stained using an ABC immunohistochemistry kit (Santa Cruz Biotechnology) and an antibody against Ki-67 [28] . TUNEL staining [29] was determined using an In situ Cell Death Detection kit (Roche Applied Science, Laval, QB). Staining intensity was assigned on a scale of 1-5 for each microscopic field and 5 fields/tumour were scored for each mouse and the average (and 95% CI) for 5 mice/condition measured.
Acridine orange and ethidium bromide microscopy B16-BL6 cell cultures were grown on glass coverslips in DMEM culture media and exposed to Thomas-EMF or sham conditions for 1 h/day for 1-5 days or to camptothecin for 6 h. The cells were incubated in 5 μg/ml acridine orange and 5 μg/ml ethidium bromide in PBS, pH 7.4, for 15 min and the green and red fluorescence visualized using an LSM510 fluorescence microscope.
DNA fragmentation assay
B16-BL6 cells, cultured on 60x15 mm plates were treated with Thomas-EMF or sham for 1 h/ day and harvested each day for 5 days. Cells treated with 6 μg/ml camptothecin for 6 or 24 h were used as a positive control. The cells were collected, lysed in TE-Triton buffer (0.2% Triton X-100, 10 mM Tris, 1 mM EDTA, pH 8.0) and subjected to centrifugation at 12,000xg for 15 min. The low molecular weight DNA-containing supernatant was treated sequentially with 50 μg/ml RNase A and 1 μg/ml proteinase K in 0.2% SDS and then precipitated using cold ethanol. The purified DNA was subjected to electrophoresis on a 1% agarose gel containing ethidium bromide.
Fluorescence microscopic detection of calcium influx
Cells were cultured on 3 cm diameter glass coverslips and then labelled by incubation in 1 μM FLUO-4(AM) calcium indicator [30] for 15 min. For some experiments, the cells were then pre-treated with activators (Bay K8644) or inhibitors (bepridil, mibefradil, nifedipine, or verapamil) of voltage-dependent Ca 2+ channels or suspending media 30 min prior to the calcium indicator. The coverslips were assembled in a Bioptechs FBS2 flow chamber on the microscope stage and exposed to sham or Thomas-EMF using a single solenoid. The background fluorescence associated with the cells was determined and images taken at 1, 15, 30, 45, and 60 min on a LSM510 fluorescence microscope with constant settings. The relative fluorescence was determined using MetaMax software and the fold increase ± SD for each time was reported for 3 independent experiments conducted on different days.
Flow cytometry analysis
B16-BL6 cells were exposed to Thomas-EMF or sham conditions for 1 h/day, collected at 0-16 h post-exposure, and fixed in 70% ethanol at -20°C. The cells were pulsed for 4 h with 10 μM BrdU at 0-12 h following EMF exposure, processed using a 5-bromo-2'-deoxy uridine labelling kit from Roche (cat 11296736001), and stained with propidium iodide before analysis on a Beckman Coulter FC500 cytometer [31] . To detect cyclin expression, fixed cells were blocked in 1% FBS in PBS, pH 7.4, labelled in anti-cyclin (A, B, D, or E) antibodies (titre 1:20, Santa Cruz Biotech, Santa Cruz, CA), and stained with appropriate FITC-or rhodamine-labelled secondary antibodies (titre 1:100) [32] . The percent positive cells (mean ± SD) relative to secondary-antibody controls was determined for 3 experiments conducted on different days.
Results
Inhibition of cancer cell proliferation following exposure to Thomas-EMF
Daily exposure of B16-BL6 mouse melanoma cell cultures to Thomas-EMF inhibited their proliferation by 45±6% after 5 days compared to sham-exposed cells (Fig 2A) . A 1 h/day exposure was sufficient since exposure for 4 h/day had the same effect. The specific time-modulated pattern of Thomas-EMF was critical since exposure to Thomas-reverse (ascending frequency modulation, 6Hz-25Hz) had no effect on B16-BL6 cell proliferation. Exposure of MDA-MB-231 and MCF-7 breast cancer cells and HeLa cervical cancer cells, to Thomas-EMF for 1 hour/day for 5 days also significantly (p<0.05) inhibited their proliferation by 30-50% compared to sham-exposed controls (Fig 2B) . However, exposure of three non-malignant cell lines, HBL-100 breast cells, HEK293 kidney cells, and HSG salivary gland cells, to Thomas-EMF had no effect on cell proliferation. Exposure to Thomas-EMF did not promote cell apoptosis or death as determined by nuclear morphology and DNA fragmentation compared to the camptothecin-treated controls (Fig 3) .
Exposure to Thomas-EMF inhibited tumour growth in mice
The effect of Thomas-EMF exposure on cancer cell growth in vivo was examined by measuring the growth of B16-BL6 cells implanted in C57b mice. The results of two studies showed that mice treated with 5-10 μT Thomas-EMF for 3 h/day had tumours that were 35-50% smaller in diameter and weight than mice exposed to sham conditions (p<0.05, Mann-Whitney U-test) (Fig 4A) . Post-hoc power calculations showed that experiment 1 had >85% power to detect differences in both tumour weight and tumour size in response to EMF treatment with 95% confidence while experiment 2 had >85% power to detect a difference in tumour size but only -6 M camptothecin for 6 h, or Thomas-EMF for 1 h/day for 1, 3, or 5 days. The cells were stained by incubation in 5 μg/ml acridine orange (green) and 5 μg/ml ethidium bromide (red) in PBS, pH 7.4 for 15 min and visualized on an LSM510 fluorescence microscope. B. B16-BL6 cells cultured in 3.5 cm culture dishes were treated with 10 -6 M camptothecin for 1, 6, or 24 h (positive control) or exposed to Thomas-EMF or sham conditions for 1 h/day for 1-5 days. Cell were collected, lysed in TE/Triton buffer (0.2% TritonX-100, 10 mM Tris, 1 mM EDTA, pH 8.0), and subjected to centrifugation at 12 000 x g for 15 min. The low molecular weight DNA was treated with RNase and proteinase K and subjected to electrophoresis on an agarose gel containing ethidium bromide. M shows the 1kb DNA marker (Life Technologies).
doi:10.1371/journal.pone.0124136.g003 a 70% power to detect a difference in tumour weight. The tumours from the EMF-treated mice were also noticeably less solid suggesting increased contributions from oedema.
Histochemical analysis of the tumours showed that TUNEL staining, which indicates DNA fragmentation [29] , was higher in Thomas-EMF-treated mice compared to sham (p<0.05) suggesting an increase in tumour cell death (Fig 4B) . Tumours isolated from the Thomas-EMF exposed mice also showed a lower level of proliferation, as indicated by decreased Ki-67 staining [28] , compared to sham-exposed mice (p<0.05).
Exposure to Thomas-EMF increased Ca 2+ uptake age dependent Ca 2+ channels (verapamil or nifedipine) had no effect (Fig 6A and S2 Fig) . The activation of the T-type Ca 2+ channels also mediated the Thomas-EMF-dependent changes in cell proliferation. Exposure of B16-BL6 cells to Thomas-EMF inhibited cell proliferation by 48±7% after 5 days. Addition of the T-type Ca 2+ channel blockers (bepridil or mibefradil), during the 1 h/day exposures, blocked the ability of Thomas EMF to decrease cell proliferation to <5% compared to sham (Fig 6B) . In contrast, treatment with the L-type channel inhibitors had no significant effect on the ability of exposure to Thomas-EMF to inhibit cell proliferation (38-43% compared to sham). Treatment of B16-BL6 cells with Bay K8644 for 1 h/day did not have a significant effect on cell proliferation (<10% on days 3 and 5) compared to daily exposure to Thomas-EMF for 1 h/day (30-40% on days 3 and 5 of treatment) (Fig 6C) .
Exposure to Thomas-EMF alters cell cycle progression
The ability of Thomas-EMF to inhibit cell proliferation without promoting cell death suggests altered cell cycle progression. Unsynchronized B16-BL6 cell cultures exposed to Thomas-EMF did not show differences in cell cycle profile (Fig 7A) . However, incubation with BrdU, which incorporates into the DNA of dividing cells, showed that exposure to Thomas-EMF slowed entry into S phase (Fig 7B) . In sham cells, BrdU staining was similar for all timepoints (44-50% positive) but Thomas-EMF-treated cells showed a significant decrease in staining for 4-8 h after exposure (24-34% positive) which was restored by 12 h post-exposure. Exposure to Thomas-EMF also promoted changes in cyclin expression. In B16-BL6 cells exposed to Thomas-EMF, the proportion of cells expressing cyclin A was decreased at 4 h post-exposure relative to the sham-treated control cells but was not different at 8 and 12 h post-exposure ( Fig  7C) . The proportion of cyclin B-expressing cells was increased at 8 and 12 h following Thomas-EMF treatment but was not altered in response to sham-treatment. The proportion of cells expressing cyclin D was significantly elevated 8 h after Thomas-EMF exposure but returned to the same level as sham-treated B16-BL6 cells by 12 h post-exposure. The proportion of cyclin E-expressing cells was elevated 12 h after Thomas-EMF treatment but remained relatively constant in response to sham-treatment.
Discussion
The results of these studies showed that exposure to a low intensity, time varying EMF, Thomas-EMF, for 1 h/day inhibited the proliferation of malignant cells by 30-50% over 5 days. Several studies have shown that exposure of cells to symmetrical (sine-wave), low intensity EMF can inhibit cell proliferation [14] [15] [16] [17] . These studies have usually involved exposure to a specific frequency of EMF between 20 and 100Hz [17, 34] ; studies using 50 and 60 Hz EMF are most common because they correlate to environmental exposures [35] . It has been proposed that these exposures decrease the growth of cell cultures by enhancing cellular apoptosis as a result of EMF-dependent increases in reactive oxygen species, rapid influx of Ca 2+ , or activation of specific signaling pathways [5] [6] [7] 36] . A variety of models to explain these changes in cellular responses have been proposed involving changes in temperature, flux density, or energy input [37] [38] [39] [40] . Some studies have shown increased expression of HSP70, a marker of cellular stress responses, in response to EMF exposures [12, 41] . Exposure to EMF (or electrical fields) has been shown to compromise plasma membrane integrity to allow influx of Ca 2+ or chemotherapeutics to enhance cell death [42, 43] . The Thomas-EMF pattern is quite different from a symmetrical EMF and the mechanism by which it affects cell proliferation also appears to be quite different from some of those proposed. The Thomas-EMF used in our experiments is a complex time-modulated pattern (25-6 HZ) which changes frequency during exposure. We have proposed that this pattern is critical for its effects on cells [10] . For example, while exposure to Thomas-EMF was able to inhibit cell proliferation, exposure to Thomas-reverse (ascending frequency, 6Hz-25Hz) did not affect cell proliferation. Since the energy profiles of these exposures are identical, the effect of the EMF was not caused by a general increase in energy exposure and was more consistent with models of stochastic resonance [8, 9] . Further, our experiments showed that exposure to Thomas-EMF did not enhance cell death as measured by the absence of apoptotic cell morphology, a sub-G1 peak on flow cytometery, and DNA fragmentation.
We also examined several cell lines to determine the generalizability of the effect of Thomas-EMF. In this study, exposure to Thomas-EMF inhibited the proliferation of the four malignant cell lines tested but did not affect the proliferation of the three non-malignant cell lines. This suggests that Thomas-EMF specifically targets some property of malignant cells and suggests it may be useful as an anti-cancer agent. This was not completely surprising since exposure to other EMF patterns (including 50 and 60 Hz EMF) have been shown to differentiate between cell types, depending on malignancy or tissue of origin, in promoting inhibition of proliferation [7, 34, 44, 45] . Some experiments had shown that EMF could promote anti-proliferative effects in leukocytes only when the cells were activated by mitogens [46] .
The ability of Thomas-EMF to inhibit the proliferation of B16-BL6 cells was also present in vivo. B16-BL6 cells implanted in syngeneic C57b mice and treated with Thomas-EMF for 3 h/ day formed tumours that were 35-50% smaller and less solid than in sham-treated mice. Since the average weight and health of the animals was not affected it appeared that exposure to Thomas-EMF did not negatively impact non-malignant tissues. The level of cell proliferation in the tumour tissues, as measured by Ki-67 expression, was decreased in Thomas-EMFexposed mice while the level of cell death, measured as DNA fragmentation using the TUNEL assay, was higher in Thomas-EMF-exposed mice. This is distinct from the in vitro data which showed no increase in DNA fragmentation and may relate to changes in leukocyte infiltration seen in Thomas-EMF-exposed mice [22] . Others have also shown that exposure to 60Hz EMF can elevate immune function in treated animals [47] and exposure to 7.5 Hz, 0.4 T EMF can inhibit B16-F10 mouse tumour proliferation while increasing T cell and dendritic cell numbers in spleen [48] . This suggests that the anti-cancer effects of EMF exposure may also have an immune component. Further, some experiments using more complex patterns, such as overlapping multiple frequencies [49] or patterns recorded from cancer cells [4, 23] [51, 52] and one study has shown that exposure of a mouse neuronal cell line to 50 Hz EMF can block Ca 2+ uptake through T-type voltage-dependent Ca 2+ channels [20] .
In these experiments, we used inhibitor studies to show that Thomas-EMF promoted Ca 2+ uptake via T-type voltage-dependent Ca 2+ channels. Pre-treatment with bepridil and mibefradil, which are well-described inhibitors of T-type channels, significantly blocked Ca 2+ uptake in response to Thomas-EMF while pre-treatment with nifedipine and verapamil, which are inhibitors of L-type channels, had no effect. This indicates that exposure to Thomas-EMF enhances Ca 2+ uptake by affecting T-type Ca 2+ channel permeability.
The Thomas-EMF-dependent effect on Ca 2+ influx appeared to be responsible for effects on cell proliferation. Blocking Ca 2+ influx through the T-type Ca 2+ channels also blocked the ability of Thomas-EMF to inhibit cell proliferation. In B16-BL6 cells treated with bepridil or mibefradil, the Thomas-EMF and sham-treated cultures grew at the same rate. In contrast, treatment of cells with inhibitors of L-type Ca 2+ channels still showed decreased proliferation when exposed to Thomas-EMF. The observation that Thomas-EMF can only impact proliferation of malignant cells may be related to the observation that many malignant cell lines and tumours aberrantly express Ttype Ca 2+ channels while non-malignant cells and HEK293 cells do not [53, 54] . For example, MCF-7 and MDA-MB-231 breast cancer cells have been shown to express T-type Ca 2+ channel subunits while non-malignant breast cells do not [55, 56] . It is not clear why cancer cells express T-type Ca 2+ channels although it has been correlated with increased malignant behaviour [56, 57] . Thus, exposure to Thomas-EMF might affect any cell that expresses the T type Ca 2+ channel, such as sensory neurons, and may explain why Thomas-EMF inhibits pain responses in animal experiments [21, 24, 58] . The idea that Thomas-EMF can slow cell proliferation via changes in cytoplasmic Ca 2+ is supported by studies that show Ca 2+ is linked to changes in cell cycle progression and cyclin expression [59, 60] . Thomas-EMF delayed S phase entry for up to 8 h after the B16-BL6 cells were exposed as shown by a decrease in BrdU incorporation and consistent with the 12 h delay in cyclin E expression [61] compared to sham controls. Further, exposure to Thomas-EMF also altered cyclins A, B, and D, expression suggesting a delay at the G2/M cell cycle transition. An elevation in cyclin D levels 8 h after exposure and in cyclin B levels [62] 8-12 h after exposure are consistent with a delay in cell cycle progression through G2. Thus, the changes in cyclin expression indicate that the Thomas-EMF treated cells are delayed by 4-8 h in passing through G1/S and M phases which could account for the decreased levels of cell proliferation seen in the treated cultures. These observations are consistent with the idea that exposure to specific EMF patterns can affect biological systems by a mechanism consistent with molecular resonance. In this case, exposure to Thomas-EMF was able to alter T-type Ca2+ channel permeability to allow an inappropriate influx of Ca 2+ which was able to disrupt proliferation of malignant cells. These observations suggest that the Thomas-EMF could provide a potential anti-cancer therapy.
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